Evotec AG and Second Genome decided to collaborate in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. The collaboration comprises the identification and optimisation of novel compounds as well as licence agreements for already existing assets developed by Evotec. Second Genome’s unique approach to identify and modulate microbiome-mediated pathways will be further enhanced by the use and the results of Evotec’s integrated drug discovery platform.
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. The company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer’s disease.
Second Genome has built a novel platform for microbiome drug discovery and is engaged in active programmes in multiple areas of significant unmet medical need.